BioPharma Credit replaces Paratek investment with new $50 million
BioPharma Credit PLC on Wednesday announced a new $50 million investment in Paratek Pharmaceuticals Inc to fund the completion of the company’s combination with Radius Health Inc.
BioPharma Credit funded $50 million in Paratek through a fully owned subsidiary, with another $50 million coming from BioPharma Credit Investments V (Master) LP, a direct lending fund often partnering with the firm.
The investment by BioPharma replaces a $25 million previous investment, which was repaid entirely by the New Paratek Financing, a debt financing from funds managed by Blackstone Inc, Sixth Street LLP, Oaktree Capital Management LP, Silver Point Capital LP, and Pharmakon Advisors LP.
With the combination with Radius Health, Paratek will add osteoporosis therapy injectable medication Tymlos to its commercial portfolio, which currently contains the intravenous pneumonia and bacterial skin infections antibiotic Nuzyra.
Radius Health is also backed by B-Flexion Life Sciences and Novo Holdings, which acquired Paratek in 2023 and turned it into a private company.
The combined company is expected to generate revenue of around $1 billion this year.
Paratek also repaid a previous $275 million senior secured facility in connection with the granting of the New Paratek Financing, to which both BioPharma Credit and BioPharma V participated with $25 million each.
BioPharma Credit received $27 million from Paratek, comprising of the principal and $2 million of prepayment fees and accrued interest.
BioPharma Credit shares were down 1.7% to 70.00p each on Wednesday afternoon in London.
Copyright 2026 Alliance News Ltd. All Rights Reserved.